Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,605
Roche Holding AG News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,633.40 | 5.00 | 0.06% |
| CAC 40 | 7,881.81 | 26.89 | 0.34% |
| DAX 40 | 21,468.74 | 40.50 | 0.19% |
| Dow JONES (US) | 44,421.91 | 122.75 | -0.28% |
| FTSE 100 | 8,563.84 | 19.72 | -0.23% |
| HKSE | 20,789.96 | 572.70 | 2.83% |
| NASDAQ | 19,391.96 | 235.49 | -1.20% |
| Nikkei 225 | 38,798.37 | 278.28 | 0.72% |
| NZX 50 Index | 12,905.04 | 94.72 | 0.74% |
| S&P 500 | 5,994.57 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,374.00 | 5.40 | -0.06% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |